TG Therapeutics Inc (TGTX)
Operating return on assets (Operating ROA)
| Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | -505 | 101,845 | 48,355 | 20,633 | -18,944 | -168,691 | -162,958 | -192,838 | -233,723 | -283,888 | -322,439 | -344,769 | -338,604 | -339,198 | -312,551 | -273,594 | -224,773 | -199,912 | -184,611 | -169,055 |
| Total assets | US$ in thousands | 586,014 | 401,207 | 373,323 | 329,587 | 331,067 | 220,854 | 197,358 | 193,572 | 217,891 | 251,666 | 303,028 | 379,629 | 409,687 | 481,400 | 548,699 | 625,642 | 273,856 | 294,621 | 101,849 | 163,014 |
| Operating ROA | -0.09% | 25.38% | 12.95% | 6.26% | -5.72% | -76.38% | -82.57% | -99.62% | -107.27% | -112.80% | -106.41% | -90.82% | -82.65% | -70.46% | -56.96% | -43.73% | -82.08% | -67.85% | -181.26% | -103.71% |
September 30, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $-505K ÷ $586,014K
= -0.09%
TG Therapeutics Inc's operating return on assets (operating ROA) has shown significant fluctuations over the past few quarters. In the most recent period as of September 30, 2024, the company reported a negative operating ROA of -0.09%, indicating that the company generated a loss from its core operations in relation to its total assets.
Looking back at the trend, in the earlier quarter as of June 30, 2024, TG Therapeutics Inc's operating ROA was positive at 25.38%, suggesting the company was efficient in generating profit from its operations relative to its assets.
However, prior to that, in the quarter ending March 31, 2024, the company's operating ROA was 12.95%, showing a lower but still positive performance in utilizing its assets to generate operating income.
The company experienced a steep decline in performance in the quarter ending June 30, 2023, with operating ROA plummeting to -76.38%, signaling significant operating losses relative to its asset base.
Overall, TG Therapeutics Inc has displayed varying levels of efficiency in utilizing its assets to generate operating income, with periods of positive returns balanced against periods of negative returns that have impacted its financial performance. Further analysis and investigation into the company's operational strategies and financial management may be required to understand the factors driving these fluctuations in operating ROA.
Peer comparison
Sep 30, 2024